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Are There Imaging Characteristics Associated with
Epidermal Growth Factor Receptor and KRAS Mutations in
Patients with Adenocarcinoma of the Lung with
Bronchioloalveolar Features?
Catherine Glynn, MBBCh, MRCPI, FRCR,* Maureen F. Zakowski, MD,†
and Michelle S. Ginsberg, MD*
Purpose: To identify any particular imaging features on computed
tomography (CT) in patients with confirmed adenocarcinoma with
bronchioloalveolar (ABAC) features and known epidermal growth
factor receptor (EGFR) and KRAS mutations.
Materials and Methods: Institutional review board approval was
obtained for this retrospective study. Seventy-seven pulmonary
nodules in 64 patients with a histologic diagnosis of ABAC and
known EGFR or KRAS mutation status were assessed. Of these, 23
patients who were negative for both EGFR and KRAS mutations
were used as a control group. Lesion size, margins, and density
(ground glass versus solid) were assessed. Statistical analysis using
the two-tailed Fisher’s exact test t test was performed with multiple
different variables.
Results: Twenty-one (33%) of 64 patients had EGFR mutations, 20
(31%) of 64 patients had a KRAS mutation, and 23 (36%) had
neither. In nine patients with an EGFR mutation, there were 10
nodules with some ground glass opacity (GGO) and in nine patients
with a KRAS mutation, there were nine nodules with some GGO.
Twenty-six (34%) of the 77 nodules had some GGO, and 12 (46%)
of these 26 nodules were entirely GGO. Sixty-two (81%) of the 77
nodules had some solid component, which also included some that
were mixed with GGO. Thirty-five (45%) of 77 nodules had air
bronchograms. All five nodules (100%) with a high percentage of
bronchioloalveolar carcinoma (75%) had the appearance of GGO
only. The presence of GGO on CT was not significantly associated
with the presence of an EGFR mutation (p  0.44) or with the
presence of a KRAS mutation (p  0.77).
Conclusions: In our sample of patients with ABAC, there was no
specific CT appearance, which would correlate with either an EGFR
mutation or a KRAS mutation, when compared with a control group
of patients who did not have these mutations.
Key Words: Bronchioloalveolar carcinoma, Adenocarcinoma of
lung, Computed tomography, Ground glass opacity, Lung nodule,
EGFR mutation, KRAS mutation.
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Lung cancer is the most common cause of cancer death inthe United States.1 Bronchioloalveolar carcinoma (BAC)
is a World Health Organization (WHO) recognized subtype
of pulmonary adenocarcinoma.2 BAC was more precisely
defined in the 1999 WHO classification as an adenocarci-
noma showing “growth of neoplastic cells along pre-existing
alveolar structures (lepidic growth), without evidence of stromal,
vascular or pleural invasion.” This definition is retained in the
2004 WHO classification. There are two histologic subtypes of
BAC, mucinous and nonmucinous, and mixed. The nonmuci-
nous subtype arises from the Clara/pneumocyte type II cell of
the bronchioles, is the more frequent form, and is associated with
ground glass opacity (GGO) on computed tomography (CT).
The less common mucinous type develops from metaplasia of
bronchiolar epithelium and is associated with a more pneumo-
nic-type pattern radiologically.
There are known differences in pathologic, radiologic,
and clinical manifestations in this pattern of lung cancer,
including a higher incidence in nonsmokers, females, and
geographical variations in incidence.
Pure BAC is rare, more recently mixed subtype adeno-
carcinomas with a bronchioloalveolar (ABAC) component
have been recognized. Different percent values for the BAC
component are assigned to quantify the amount of BAC. It
seems that both pure BACs and ABAC are more common in
Japan than in other countries.3 Radiologically, pure BAC can
appear as a solitary nodule (Figure 1), consolidation (either
segmental or lobar) (Figure 2), or in a diffuse multicentric
form4,5 (Figure 3).
The activity of epidermal growth factor and its receptor
(EGFR) have been identified as key drivers in the process of
cell growth and replication. Heightened activity at the EGFR
can lead to an increase in the drive for the cell to replicate.
There is now a body of evidence to show that the EGFR-
mediated drive is increased in a wide variety of solid tumors,
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including non-small cell lung cancer, prostate, breast, gastric,
colon, and ovarian cancers, and in tumors of the head and neck.6
Studies have found a correlation between the presence
of EGFR mutations and the presence of a BAC growth pattern,
either as a pure growth pattern or in ABAC growth.7–10 KRAS is
an oncogene contributing to the development of cancer, usually
as a mutated form of a normal cellular gene. It has a mutually
exclusive mutation with EGFR.11 Tumors with this mutation
seem to be less responsive to tyrosine kinase inhibitors (TKIs),
a therapy to which EGFR positive tumors are more likely to
respond. To our knowledge, there have been no published
studies specifically evaluating a correlation between the radio-
logic appearance of ABAC with EGFR or KRAS mutation
status. In this study, we wanted to correlate the CT appearances
with the subsequent pathology and both EGFR and KRAS status
and to identify any particular imaging features associated with
these mutations.
PATIENTS AND METHODS
This study was performed with a waiver approval from
our institutional review board for a retrospective study. EGFR
and KRAS mutations were not routinely analyzed in our institu-
tion before January 2006. A text string search of the pathology
database from January 1, 2006, to November 13, 2007, identi-
fied cases with a histologic diagnosis of ABAC and yielded 180
patients. From January 1, 2006, onward, the EGFR and KRAS
status of the patients was documented (positive, negative, and
not done) on the 180 patients.
Inclusion criteria were an available pathology report,
preoperative CT images on our Picture Archiving and Com-
munication System (PACS, GE Centricity RA100), and avail-
able test results for EGFR and KRAS mutations.
Exclusion criteria included those cases that did not go
to surgery and therefore had no pathologic specimen, cases
where there was no presurgical CT on the hospital PACS, and
when there was a duration greater than 3 months between the
CT and the subsequent surgery. Cases with multiple lesions
on CT which individually could not be conclusively corre-
FIGURE 2. Consolidation with air bronchograms right
lower lobe.
FIGURE 1. Solid lesion right lower lobe, paramediastinal
location.
FIGURE 3. Extensive ground glass opacity left upper lobe,
with subcentimeter foci of ground glass opacity also present
in the right upper lobe.
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lated with the lesions documented in the pathology report
were also excluded.
The remaining studies were then retrieved on the radi-
ology PACS and the images reviewed by two radiologists in
consensus (M.G., thoracic radiologist with 17 years of expe-
rience and C.G., a radiology fellow). Radiologic parameters
such as number of lesions, location, size, lesion margin, and
density were recorded for each patient. The technical CT
imaging parameters recorded included whether the study was
from our institution or an outside hospital, slice thickness, the
use of intravenous iodinated contrast, and the date of the study
with respect to the date of the surgical pathology specimen.
In a few cases, the only preoperative imaging available
was a positron emission tomogram with a noncontrast-en-
hanced CT for anatomic location (PET-CT). In these cases,
the CT from the PET-CT study was used to characterize the
lesions if deemed adequate for interpretation and character-
ization, otherwise these cases were excluded. Finally, there
were a total of 64 patients with 77 lesions reviewed. One
hundred sixteen cases were excluded as the CT scans were
obtained at another institution and not available in our PACS.
Lesion size was categorized as0.5, 0.5 to 1, and1.1
cm. The largest diameter measurements were obtained man-
ually using the PACS measurement electronic tool in all
cases. Lesion density was categorized as solid, part solid,
ground glass, consolidation, and the presence of air bron-
chograms. GGO on CT was defined as a hazy increase in lung
density without obscuration of the pulmonary vessels. Con-
solidation on CT was defined as increased density of the lung
parenchyma with obscuration of the pulmonary vessels. Air
bronchograms on CT were defined as air-filled bronchi seen
as radiolucent, branching bands within pulmonary densities.
Lesion margins were categorized as spiculated, smooth,
or lobular. Smooth lesions were defined as those where one
can clearly outline the lesion radiologically without any
spiculations into the surrounding tissue being evident. A
maximum of three lesions per patient were included, which
could accurately be correlated with the resected lesions if
specific lobe localization could be made. Examples of CT
appearances of these various lesions are demonstrated in
Figures 1 to 5.
Regarding the histopathology of the cases, the follow-
ing details from the surgical specimen pathology report were
recorded: whether BAC was present and in what percentage
of the sample, whether there was a mucinous or nonmucinous
component (if documented), and whether other adenocarci-
noma histologic subtypes were present, such as acinar, pap-
illary, micropapillary, or solid subtypes. Although the major-
ity of patients had a biopsy before surgery, the resected
surgical pathologic report was used for the relative amounts
of histologic subtypes present. The EGFR and KRAS muta-
tion status for the resected tumors was also documented.
Patients positive for EGFR were not tested for KRAS as the
mutations are mutually exclusive.
Statistical analysis using the two-tailed Fisher’s exact
test t test was performed with multiple different variables
including ground glass and solid appearance on CT, high
percentage BAC-containing lesion versus lower percentage
BAC lesions, lesion size, and EGFR or KRAS mutations. A
cutoff of 75% BAC was determined to represent a high
percentage of BAC subtype in a given lesion.
FIGURE 4. Mixed lesion with both solid and ground glass
components.
FIGURE 5. Ground glass opacity nodule posterior right up-
per lobe.
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RESULTS
There were 77 lesions assessed in 64 patients (M:F 
17:47) (Table 1). There were 23 patients who were negative
for both EGFR and KRAS mutations and were used as a
control group. The EGFR and KRAS mutation status of the
patients who had more than one lesion were only counted
once per patient and not counted per lesion.
Twenty-one patients were EGFR positive (exon 19
positive, n  9; exon 21 positive, n  12), and 42 patients
were EGFR negative. There were 29 lesions in 20 KRAS-
positive patients, which accounted for 38% of the 77 lesions.
Twenty-four patients tested negative for KRAS mutation (Ta-
ble 1). Two patients who were EGFR positive but were tested
for KRAS, and were KRAS negative, had a KRAS test failure
in one patient.
Only 12 cases had pathology reports stating whether the
tumor was mucinous or nonmucinous, too small a number to
make any assessment of significant association with KRAS or
EGFR mutation status.
The majority of pulmonary nodules had combined
radiologic features (Table 2). For example, a nodule could
have both air bronchograms and a solid appearance. Twenty-
six (34%) of the 77 nodules had some GGO, and 12 (46%) of
these 26 nodules were entirely GGO. Sixty-two (81%) of the
77 nodules had some solid component, which also included
some that were part solid (mixed GGO). Thirty-five (46%) of
77 nodules had air bronchograms (Table 2).
We also evaluated cases where a high proportion of
BAC (75%) was documented in the pathology report (n 
5) to assess whether the high percentage of BAC gave rise to
a particular CT appearance (Table 3). There was no pure,
100% BAC lesion in our sample; the highest percentage of
BAC documented was 90%.
Eighty percent of high percentage BAC lesions were
found in female patients. All five nodules (100%) with a high
percentage of BAC had the appearance of GGO only (Table 3).
Using the two-tailed Fisher’s exact test t test, many
different variables were tested to assess for correlation with
mutation status. The presence of GGO on CT was not
significantly associated with the presence of an EGFR muta-
tion (p 0.44) or with the presence of a KRAS mutation (p
0.77) (Table 4). Three of the five (60%) predominantly BAC
lesions were positive for KRAS mutation, whereas only one
(20%) was positive for an EGFR mutation. This was not
statistically significant (p  0.5). There was no correlation
between a solid appearance of a nodule on CT and EGFR or
KRAS mutation being present (p  1 for EGFR and p  0.75
for KRAS). There was no correlation between lesions con-
taining a high percentage of BAC (75%) versus those with
75% BAC and an EGFR or KRAS mutation being present
(p  0.64 for EGFR and p  0.62 for KRAS, respectively).
There was no statistically significant correlation be-
tween a size of a nodule on CT and EGFR or KRAS mutation
TABLE 1. Patient Demographics
Males
(n  17)
Females
(n  47)
Mean age (yr) 68.5 67.3
Age range (yr) 54–87 41–87 41–87
EGFR mutation positive 4 17 21 (32.8%)
EGFR mutation negative 13 30 43 (67.2%)
KRAS mutation positive 4 16 20 (31.25%)
KRAS mutation negative 9 15 24a (37.5%)
KRAS test failure in one male patient is not included.
a Twenty-four patients tested negative for KRAS mutation. Two patients who were
EGFR positive but were tested for KRAS and were KRAS negative had a KRAS test
failure in one patient.
EGFR, epidermal growth factor receptor.
TABLE 2. Imaging Characteristics of Nodules on CT
Imaging
Characteristics
Total, n  77
Nodules (%)
EGFR
Negative
EGFR
Positive
KRAS
Negative
KRAS
Positive
Solid 52 (68) 38 14 16 21
Part solid 10 (13) 5 5 4 1
Any ground glass
opacity (GGO)
26 (34) 16 10 9 9
Consolidation 2 (3) 2 0 0 2
Air bronchograms 35 (46) 22 13 9 13
EGFR, epidermal growth factor receptor.
TABLE 3. High % BAC Cases (n  5)
% BAC
Male/
Female
EGFR Exon
19 Mutation
EGFR Exon
21 Mutation
KRAS
Mutation
CT
Density
% Mucinous/
Nonmucinous
80 Male    GGO only Nonmucinous
80 Female    GGO only Not documented
80 Female   GGO only Not documented
80 Female    GGO only Not documented
90 Female    GGO only Not documented
, negative for mutation; , positive for mutation.
BAC, bronchioloalveolar carcinoma; CT, computed tomography; EGFR, epidermal growth factor receptor; GGO, ground glass opacity.
TABLE 4. Ground Glass Opacity and EGFR and KRAS
Mutation Analyses of Nodules
Imaging
Features
Total No.
of Nodules
(n  77)
EGFR
Negative
EGFR
Positive
KRAS
Negative
KRAS
Positive
Any GGO 26 16 10 9 9
No GGO 51 37 14 16 20
EGFR, epidermal growth factor receptor.
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being present (p  0.6 for EGFR and p  0.18 for KRAS,
respectively).
DISCUSSION
In recent years, mutations in the EGFR status of ade-
nocarcinoma lesions have been described. These mutations
are detected in 10 to 15% of all patients with adenocarcinoma
and in 80% of patients who clinically respond to EGFR TKIs
gefitinib or erlotinib.11–15 These mutations are located in
exons 18 to 21 of the EGFR tyrosine kinase domain, with
deletions in exon 19 and nucleotide substitutions in exon 21
being the most common mutations of the EGFR. These
mutations are known to be increased in patients with BAC
and ABAC. In contrast, lung adenocarcinomas that are re-
fractory to TKI therapy often have mutations in KRAS but
lack EGFR mutations.16 The radiologic appearance of these
lesions would potentially be useful in raising this mutation
possibility. This in turn may allow medical oncologists to
consider the use of targeted therapies sooner in these patients.
It is important to be able to select individual patients who are
likely to benefit from a therapy and conversely, equally
important to be able to identify those who are unlikely to
respond to a particular treatment. Work is ongoing on devel-
oping other methods of imaging the metabolic aspects of lung
cancers. For example, developing EGFR-targeted PET is a
possibility which is being actively studied.17
Additionally, EGFR-directed therapies seem to have
the highest response rate in tumors that are pure nonmucinous
BAC or have a prominent BAC component.7,8,10,17 In addition
to correlation with a BAC growth pattern, EGFR mutations
have been reported more frequently in women, nonsmokers,
and Asian patients.7,8,10,18 A study by Shigematsu et al.11 did
not identify a correlation with EGFR mutation and the pres-
ence of a BAC pattern but did find an association with female
sex, nonsmoking status, and Asian ancestry, as seen in other
studies. Multiple studies have found a clinicopathologic cor-
relation between BAC and ABAC tumors and EGFR muta-
tions. Also BAC and ABAC tumors are known to have a
particular appearance on CT, which includes the appearance
of ground glass. Therefore, one would anticipate that GGO on
CT would be directly associated with an EGFR mutation on
subsequent pathologic testing. In our sample of patients with
ABAC, there was no specific CT appearance that would
correlate with either an EGFR mutation or a KRAS mutation,
when compared with a control group of patients who also had
ABAC but did not have these mutations. There are a few
possible reasons for this. First, our sample size was relatively
small. This likely contributed to our inability to achieve a
statistically significant correlation. Our small sample size was
smaller than the initially identified group because many
patients did not have preoperative imaging studies at our
institution. These studies were either not available on our
PACS or were deemed to be of inappropriate quality for
interpretation of such subtle findings as ground glass density.
We are a major tertiary cancer referral center and many of our
patients have imaging performed before presentation to our
institution.
We found no CT characteristics of pulmonary nodules
in patients with ABAC that could help suggest the status of an
EGFR or KRAS mutation. Further prospective studies with
larger number of patients are warranted.
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